{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:35Z","timestamp":1787026655319,"version":"build-2736575974"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Pancreatic cancer (PC) remains one of the most challenging cancers and has the worst prognosis. Tumor-associated MUC1 (tMUC1) is overexpressed and aberrantly glycosylated in over 80% of human pancreatic ductal adenocarcinoma (PDA). Chimeric antigen receptor (CAR) engineered T cells are an emerging cancer immunotherapy strategy and recently, we successfully engineered tMUC1-specific human and mouse CAR T cells and demonstrated their effectiveness as monotherapy against PDA\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    . In this study, we observed varying sensitivity among human PDA cell lines in response to tMUC1-targeted CAR T cell cytolysis. Notably, highly resistant HPAFII cells released greater amounts of interferon (IFN)-regulated ICAM-1, CXCL10, and CXCL11 compared to the more sensitive MiaPaCa-2 cells following CAR T cell challenge. Blocking IFN signaling using Ruxolitinib, a JAK1\/2 inhibitor (JAKi), significantly reduced the upregulation of ICAM-1 and CXCL10. Western blot analysis revealed that both type I and type II IFN signaling pathways were elevated in PDA cells upon CAR T cell treatment. JAKi effectively suppressed this signaling response, with a more pronounced impact on the type I IFN pathway. Importantly, both IFN blockade and transient knockdown of IFN receptors significantly enhanced the sensitivity of PDA cells to CAR T cell-mediated cytolysis\n                    <jats:italic>in vitro<\/jats:italic>\n                    . Further mechanistic study revealed that CAR T cells partially lose their cytolytic potential after engaging with PDA cells. Treatment with CAR T cells triggered the up-regulation of immune checkpoint PD-L1 expression on PDA cells via tumor cell\u2019 own IFN signaling. Thus, blocking PD-L1 in HPAFII enhanced its response to CAR T cells. Similarly, neutralizing CXCL10 enhanced CAR T cell killing of HPAFII cells suggested CXCL10\u2019s involvement in resistance to CAR T cell cytolysis. RNA-seq data indicated higher expression of multiple genes along the IFN signaling pathway which were associated with poor prognosis in PDA patients. Taken together, tumor intrinsic IFN signaling may drive immune evasion in PDA cells against tMUC1-targeted T cell-mediated immunotherapy. This identifies tumor IFN signaling as a potential therapeutic target to improve CAR T cell efficacy in PDA treatment.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1618415","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T05:27:20Z","timestamp":1754630840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor-intrinsic interferon signaling drives pancreatic cancer resistance to tumor mucin1-targeted CAR T cell therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Ru","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Mayberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taina","family":"Firmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinku","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Network Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2022","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj013","article-title":"The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review","volume":"17","author":"Stefanidis","year":"2006","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s1072-7515(99)00075-7","article-title":"Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985\u20131995, using the National Cancer Database","volume":"189","author":"Sener","year":"1999","journal-title":"J Am Coll Surgeons."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2002\/174320","article-title":"Pancreatic cancer: who benefits from curative resection","volume":"16","author":"Beger","year":"2002","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880315)61:6<1110::aid-cncr2820610610>3.0.co;2-6","article-title":"External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer","volume":"61","author":"Roldan","year":"1988","journal-title":"Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1586\/14760584.4.4.493","article-title":"MUC1 as a target antigen for cancer immunotherapy","volume":"4","author":"Acres","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"B9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1517\/14712598.2012.725719","article-title":"MUC1 immunotherapy is here to stay","volume":"13","author":"Kimura","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1023\/a:1011379725811","article-title":"MUC1, the renaissance molecule","volume":"6","author":"Gendler","year":"2001","journal-title":"J Mammary Gland Biol Neoplasia."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.013292","article-title":"MUC1 and MUC2 in pancreatic neoplasia","volume":"57","author":"Levi","year":"2004","journal-title":"J Clin Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11857","article-title":"MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration","volume":"99","author":"Chhieng","year":"2003","journal-title":"Cancer."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1021\/pr0499085","article-title":"Comprehensive proteomic analysis of human pancreatic juice","volume":"3","author":"Gr\u00f8nborg","year":"2004","journal-title":"J Proteome Res"},{"key":"B14","article-title":"Tumor specific antibodies and uses therefor","author":"Mukherjee","year":"2013","journal-title":"Google Patents;"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193260","article-title":"Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004","volume":"13","author":"Wu","year":"2018","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.516","article-title":"A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/cells8091070","article-title":"Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma","volume":"8","author":"Yazdanifar","year":"2019","journal-title":"Cells."},{"key":"B19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/jci91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature."},{"key":"B24","article-title":"Enhancement of metastatic potential by \u03b3-interferon","volume":"51","author":"Kelly","year":"1991","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2011.91","article-title":"Induction of metastatic cancer stem cells from the NK\/LAK-resistant floating, but not adherent, subset of the UP-LN1 carcinoma cell line by IFN-\u03b3","volume":"91","author":"Chen","year":"2011","journal-title":"Lab Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-019-0224-x","article-title":"Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade","volume":"29","author":"Jacquelot","year":"2019","journal-title":"Cell Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell."},{"key":"B28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"biomark Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01315-x","article-title":"In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer","volume":"23","author":"Dubrot","year":"2022","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pharmthera.2016.06.008","article-title":"Targeting tumor tolerance: A new hope for pancreatic cancer therapy","volume":"166","author":"Delitto","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01149","article-title":"CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00883-2","article-title":"The NCI genomic data commons","volume":"53","author":"Heath","year":"2021","journal-title":"Nat Genet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas Pan-Cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat Genet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics."},{"key":"B35","article-title":"Modeling survival data: extending the cox model","volume":"20","author":"Borgan","year":"2001","journal-title":"Stat Med"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1201\/9780429192760","volume-title":"Statistical computing with R: chapman and hall\/CRC","author":"Rizzo","year":"2019"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.11.009","article-title":"CXCR3 ligands in disease and therapy","volume":"26","author":"Van Raemdonck","year":"2015","journal-title":"Cytokine Growth factor Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.141.5.1665","article-title":"Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies","volume":"141","author":"Rothlein","year":"1988","journal-title":"J Immunol (Baltimore Md: 1950)."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149346","article-title":"Endothelial STING controls T cell transmigration in an\nIFNI-dependent manner","volume":"6","author":"Anastasiou","year":"2021","journal-title":"JCI Insight"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03379-6","article-title":"Radiotherapy enhances CXCR3(high)CD8(+) T cell activation through inducing IFN\u03b3-mediated CXCL10 and ICAM-1 expression in lung cancer cells","volume":"72","author":"Wang","year":"2023","journal-title":"Cancer Immunol Immunother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"11720","DOI":"10.1038\/s41598-018-29604-2","article-title":"ICAM1 expression is induced by proinflammatory cytokines and associated with TLS formation in aggressive breast cancer subtypes","volume":"8","author":"Figenschau","year":"2018","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202222","article-title":"CD8+ T cells produce the chemokine CXCL10 in response to CD27\/CD70 costimulation to promote generation of the CD8+ effector T cell pool","volume":"191","author":"Peperzak","year":"2013","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat Rev Cancer."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1023177","article-title":"The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S353489","article-title":"Role of JAK2\/STAT3 signaling pathway in the tumorigenesis, chemotherapy resistance, and treatment of solid tumors: A systemic review","volume":"15","author":"Mengie Ayele","year":"2022","journal-title":"J Inflammation Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1151862","article-title":"Editorial: The role of STAT3 signaling pathway in tumor progression","volume":"13","author":"Chang","year":"2023","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-10-0502","article-title":"JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling","volume":"10","author":"Song","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-14-0077","article-title":"Targeting JAK1\/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer","volume":"13","author":"Wen","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B53","doi-asserted-by":"publisher","first-page":"12827","DOI":"10.3390\/ijms222312827","article-title":"The MTT assay: utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis","volume":"22","author":"Ghasemi","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1618415\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T05:27:22Z","timestamp":1754630842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1618415\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2025.1618415"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1618415","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"article-number":"1618415"}}